Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
The German Federal Joint Committee (G-BA) plans to decide on reimbursement of breast cancer biomarker tests in Q4.
The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.
The company's total revenues were $23.1 million, supported by growth across the firm's instrument and consumables sales, and its research collaboration business.